Journal article
Necrosis predicts benefit from hypoxia-modifying therapy in patients with high risk bladder cancer enrolled in a phase III randomised trial.
- Abstract:
-
BACKGROUND AND PURPOSE: Addition of carbogen and nicotinamide (hypoxia-modifying agents) to radiotherapy improves the survival of patients with high risk bladder cancer. The study investigated whether histopathological tumour features and putative hypoxia markers predicted benefit from hypoxia modification. MATERIALS AND METHODS: Samples were available from 231 patients with high grade and invasive bladder carcinoma from the BCON phase III trial of radiotherapy (RT) alone or with carbogen and...
Expand abstract
- Publication status:
- Published
Actions
Authors
Bibliographic Details
- Journal:
- Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
- Volume:
- 108
- Issue:
- 1
- Pages:
- 40-47
- Publication date:
- 2013-07-01
- DOI:
- EISSN:
-
1879-0887
- ISSN:
-
0167-8140
- Source identifiers:
-
405914
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:405914
- UUID:
-
uuid:d701436d-8ba0-4988-b0df-1d39d7de0bfe
- Local pid:
- pubs:405914
- Deposit date:
- 2013-11-16
Terms of use
- Copyright date:
- 2013
If you are the owner of this record, you can report an update to it here: Report update to this record